Development of randomized trials in adults with medulloblastoma—the example of eortc 1634-btg/noa-23

Peter Hau*, Didier Frappaz, Elizabeth Hovey, Martin G. McCabe, Kristian W. Pajtler, Benedikt Wiestler, Clemens Seidel, Stephanie E. Combs, Linda Dirven, Martin Klein, Antoinette Anazodo, Elke Hattingen, Silvia Hofer, Stefan M. Pfister, Claus Zimmer, Rolf Dieter Kortmann, Marie Pierre Sunyach, Ronan Tanguy, Rachel Effeney, Andreas von DeimlingFelix Sahm, Stefan Rutkowski, Anna S. Berghoff, Enrico Franceschi, Estela Pineda, Dagmar Beier, Ellen Peeters, Thierry Gorlia, Maureen Vanlancker, Jacoline E.C. Bromberg, Julien Gautier, David S. Ziegler, Matthias Preusser, Wolfgang Wick, Michael Weller

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

9 Citations (Scopus)
5 Downloads (Pure)


Medulloblastoma is a rare brain malignancy. Patients after puberty are rare and bear an intermediate prognosis. Standard treatment consists of maximal resection plus radio-chemother-apy. Treatment toxicity is high and produces disabling long-term side effects. The sonic hedgehog (SHH) subgroup is highly overrepresented in the post-pubertal and adult population and can be targeted by smoothened (SMO) inhibitors. No practice-changing prospective randomized data have been generated in adults. The EORTC 1634-BTG/NOA-23 trial will randomize patients between standard-dose vs. reduced-dosed craniospinal radiotherapy and SHH-subgroup patients between the SMO inhibitor sonidegib (Odomzo™, Sun Pharmaceuticals Industries, Inc., New York, USA) in addition to standard radio-chemotherapy vs. standard radio-chemotherapy alone to improve outcomes in view of decreased radiotherapy-related toxicity and increased efficacy. We will further investigate tumor tissue, blood, and cerebrospinal fluid as well as magnetic resonance imaging and radiotherapy plans to generate information that helps to further improve treatment outcomes. Given that treatment side effects typically occur late, long-term follow-up will monitor classic side effects of therapy, but also health-related quality of life, cognition, social and professional outcome, and reproduction and fertility. In summary, we will generate unprecedented data that will be trans-lated into treatment changes in post-pubertal patients with medulloblastoma and will help to design future clinical trials.

Original languageEnglish
Article number3451
Issue number14
Publication statusPublished - 9 Jul 2021

Bibliographical note

Funding: This research is funded by Deutsche Krebshilfe, grant number 70113453; by Canteen Australia; by Cancer Australia, grant number 1165910; by the Dutch Cancer Society, grant number 2021-1/13555; by the French Ministry of Health, grant number PHRC-K20-179; by the Swiss Brain Tumor Foundation; by an internal grant of the EORTC Brain Tumor Group, and by an educational grant of Sun Pharmaceuticals Industries Ltd.

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


Dive into the research topics of 'Development of randomized trials in adults with medulloblastoma—the example of eortc 1634-btg/noa-23'. Together they form a unique fingerprint.

Cite this